PRMT1 and cancer: By dissecting a particular SE-regulated cascade, we have identified PRMT1 as a downstream druggable target that could be used to intercept SE-driven cancers while potentially avoiding some of the severe toxicities that have emerged from other clinical SE-targeted therapies.